Skip over generic navigation
Skip over primary navigation
Skip over visual
Skip over functional column
PARSIPPANY, N.J., November 18, 2011
Evonik Industries AG has announced the successful acquisition of the assets of SurModics Pharmaceuticals, Inc., a subsidiary of SurModics, Inc., by and through its U.S. affiliate Evonik Degussa Corporation. The acquisition gives Evonik ownership of SurModics’ parenteral dosage forms services and bioresorbable polymers business. The new Evonik site will be named Birmingham Laboratories. All employees of SurModics Pharmaceuticals, Inc., will transfer to Evonik, assuring full business continuity from the first day. The Birmingham, Alabama-based business will be integrated in Evonik Degussa Corporation, headquartered in Parsippany, N.J. For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition; resource efficiency; and globalization. In 2010 about 80 percent of the Group’s chemicals sales came from activities where it ranks among the market leaders. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.